Anatara Lifesciences (ASX:ANR) received a patent for its Gastrointestinal ReProgramming (GaRP) product, under the invention title "Gastrointestinal Health Composition," according to a Tuesday filing with the Australian bourse.

The intellectual property protection, granted by the Australian Patent Office, has a 20-year term from Oct. 9, 2020, to Oct. 9, 2040, the filing said.

The GaRP product is a complementary medicine designed to tackle the root causes of chronic gastrointestinal conditions like irritable bowel syndrome and inflammatory bowel disease, per the filing.

Its shares fell 8% in afternoon trade Wednesday.